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ABSTRACT
Objectives: The paper assess the relevance of HR HPV E6/E7 mRNA test in women with abnormal Pap results.
Material and methods: Between 2013–2014, 125 women were subjects to the enhanced diagnostics due to abnormal Pap 
results. According to The Bethesda system, if ASC-US, AGC, LSIL, ASC-H, HSIL or cancer cells were present, the result was 
abnormal. The patients underwent the enhanced diagnostics which included the following procedures: Pap smear collection 
for molecular assessment of HR HPV E6/E7 mRNA test, the colposcopic examination and biopsy of clinically suspicious areas.
Results: High-grade squamous intraepithelial lesions constituted the most frequent cervical pathology in women with 
abnormal Pap test results, as well as with the positive results of HR HPV E6/E7 mRNA test. Test sensitivity in patients with 
the histopathological diagnosis of high-grade squamous intraepithelial lesion was estimated at 86.1%.
Conclusions: HR HPV E6/E7 mRNA test identifying neoplastic lesions and cervical cancer is characterised by a high relevance 
which is reflected by means of sensitivity and specificity. In fact, test sensitivity and specificity increased with the age in 
the group of patients up to 50 years old. 
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INTRODUCTION
According to the World Health Organization (WHO), 
cervical cancer constitutes the 4th most frequent malignant 
cancer in women worldwide. In 2012, about 530000 new 
cases were recorded, and nearly 90% of 270000 deaths oc-
curred due to this disease in mid and low socioeconomic 
status countries. Moreover, high mortality rate may be 
reduced only if a comprehensive approach is introduced 
including broadly defined prevention, that is education, 
effective and efficient screening, as well as early diagnosis 
and treatment [1].
The introduction of cervical cancer screening has largely 
decreased both the incidence and the mortality rate of women 
in Europe over the years, although the success rate is radically 
different in particular countries [2]. Nowadays, 34000 new 
cases of cervical cancer are found in Europe every year, with 
13000 deaths due to this disease [3]. In Poland, since the 90’s 
the tendency constantly decreases, reflecting the improve-
ment in the epidemiological situation, although further steps 
need to be taken in order for the method to be fully successful. 
In Poland in 2014, the diagnosis of cervical cancer was made 
in 9 women a day, and nearly half of them died of it. [4, 5].
In 2005 a Polish national programme for cervical can-
cer prevention was implemented which aimed at an early 
detection of precancerous lesions classified as CIN (Cervical 
Intraepithelial Neoplasia) 1, CIN 2, CIN 3. According to the 
current recommendations, CIN 1 is referred to as LG SIL 
(Low Grade Squamous Intraepithelial Lesion), whereas CIN 
2 and CIN 3 are both called HG SIL (High Grade Squamous 
Intraepithelial Lesion). 
The basic factor in cervical cancer development is a per-
sistent infection with HR HPV, where the most cancerogenic 
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types are HPV 16, 18, 31, 33, 45. Cervical intraepithelial neo-
plasia lasts ca. 7–10 years, and following another 3–5 years 
may consequently lead to a pre-invasive and invasive cervi-
cal cancer. Moreover, current data indicate the presence of 
various HPV DNA types in 99.7% cervical cancer biopsies [6].
As early as 2003, the American College of Obstetricians 
and Gynecologists was the first to include HR HPV DNA test 
in the screening guidelines. Furthermore, since 2012 more 
and more recommendations have indicated and proved the 
HPV DNA test superiority over conventional cytology test in 
female patients aged 30–65 [7].
There is evidence suggesting that co-testing, i.e. com-
bining Pap test with HR HPV DNA test, contributes to a de-
crease in the incidence of invasive cancer, as well as gen-
erates lower costs in comparison to the annual Pap test 
performed for 30 years [8, 9].
The current European guidelines recommend HR HPV 
DNA test as a screening method in women 35–60 years of 
age [10]. 
Numerous research indicate a higher diagnostic value of 
the HR HPV DNA test in comparison with the Pap test. In fact, 
on the basis of the analysis including over 10000 women 
in Canada, HR HPV DNA test sensitivity for HG SIL lesions 
was estimated at 94.6%, as compared to cytological test 
sensitivity which was estimated at 55.4% [11].
A perfect screening method should comprise a nearly 
100% sensitivity and specificity, as well as a high positive 
predictive value which in practice, however, is extremely 
difficult to obtain. 
Incorporating tests detecting HR HPV E6/E7 mRNA 
test constitutes one of the most recent discoveries, and 
allows for the identification of patients with permanent 
viral infection, where the process of DNA incorporation in 
the epithelial cells genetic material has already been initi-
ated. In fact, the neoplastic transformation process starts 
once HPV DNA integrates with the proper epithelial cell 
genome. Moreover, it is possible when HPV DNA circular 
form is damaged and chromatin displacement occurs 
within the chromosomal DNA of host’s cells. Oncoprotein 
E6 and E7 expression in epithelial cells infected with HR 
HPV types is associated with an increase in prolifera-
tion and abnormal differentiation of these cells, and may 
lead to the development of neoplastic and malignant 
lesions  [12–14]. HR HPV E6 protein contributes to the 
degradation of p53 protein which protects the genome, 
an thus may inactivate the genetic mechanisms control-
ling the cellular cycle and apoptosis. In fact, the function 
of p53 in the cellular cycle is based on the movement con-
trol from G1 phase to the S phase of the cellular cycle by 
means of inducing expression of p16, p21 and p27 cyclin 
inhibitors. Due to this mechanism it is possible to stop 
the cellular cycle in G1/S phase [12].
According to the sources, the described diagnostic pro-
cedure is characterised by a high sensitivity and specificity 
equal to 98% and 85% respectively. 
The indisputable advantage of the abovementioned 
diagnostic method is the objectivity and repeatability, al-
though the screening test of a given patient would not have 
to be performed as frequently as a conventional cytology. 
The clinical observations show that the progression risk 
increases when one of the highly oncogenic types: 16, 18, 
31, 33, 45 is responsible for the persistent infection, and 
its mRNA presence constitutes an even poorer prognostic 
factor. In fact, it indicates an ongoing carcinogenesis on the 
molecular level and additionally, in 98% of cases, it entails 
the continuation and progression of the disease [15]. Further 
observations may be vital in the future, and may result in 
the introduction of new guidelines in patients diagnosed 
with LG SIL who may undergo a spontaneous regression in 
certain cases. Moreover, observation of regression in women 
with a negative HR HPV E6/E7 mRNA test could prevent 
them from additional stress and the necessity of performing 
unnecessary invasive procedures. 
Objectives 
The aim of the paper is to assess the relevance of HR HPV 
E6/E7 mRNA test in women, in female patient population 
with abnormal Pap test. 
MATERIAL AND METHODS
Between 2013–2014 in the Laboratory of Pathophysi-
ology of Uterine Cervix at Poznań University of Medical 
Sciences, 125 women were subjects to the enhanced diag-
nostics due to abnormal cytology results. According to The 
Bethesda system, if ASC-US, AGC, LSIL, ASC-H, HSIL or cancer 
cells were present, the result was abnormal. All women who 
participated in the study were adults, not pregnant and not 
breast-feeding. The study was approved by the Bioethics 
Committee of the University No 548/18. The paper consti-
tutes a retrospective analysis.
Firstly, all patients were subjects to a detailed medical 
interview which included the oncological past, earlier cy-
tology and histopathological tests results, if they had been 
performed, family history, obstetric history, the age of the 
first menstruation and the date of the last menstrual period. 
Secondly, the patients underwent the enhanced diagnostics 
which included the following procedures:
 Ū Pap smear collection for molecular assessment of HR 
HPV E6/E7 mRNA test;
 Ū The colposcopic examination;
 Ū Biopsy of clinically suspicious areas assessed by a gy-
naecologist.
Pap smear for molecular assessment — the sample was 
collected with an endocervical Cyto-Brush, and then it was 
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preserved in PreservCyt® (Hologic Corp.) and SurePath® (BD 
Diagnostics-TriPath) reserved for the biological material. Nu-
cliSENS EasyQ® HPV v1.1 test by bioMérieux was employed 
for the detection and nucleic acid amplification in real-time, 
allowing for qualitative identification of E6/E7 messenger 
RNA (mRNA) for five cancerogenic HPV virus types: 16, 18, 
31, 33, 45 in epithelial cells. 
Colposcopic examination — the examination was per-
formed in the Laboratory of Pathophysiology of Uterine 
Cervix by means of the stereoscopic colposcope Olympus 
OSC-500. In fact, the visualization of the affected area is cru-
cial for the examination to be satisfactory. In all cases, a trial 
with 3% aqueous solution of acetic acid was performed, as 
well as the Schiller’s test with Lugol’s iodine. The colposcopic 
images were evaluated according to Reid’s Colposcopic 
Index which assesses the colour, lesion borders and surface, 
blood vessels and iodine test.
Biopsy of the clinically suspicious area visible in col-
poscopy was performed in each patient classified for the 
examination. Cervical samples were fixed in buffered 10% 
formalin solution.
Calculations were performed using the statistical pack-
age Statistica (data analysis software system), ver. 13.1 and 
graphs — using Excel. It was estimated whether increasing 
age resulted in higher rates of sensitivity, specificity, PPV and 
NPV by Chi-square test for the trend. Statistical hypotheses 
were verified at the level of significance of = 0.05. 
RESULTS
120 patients participated in the study who were classi-
fied into 4 age groups:
 Ū 18–29 years of age → n = 50,
 Ū 30–39 years of age → n = 42,
 Ū 40-49 years of age → n = 15,
 Ū over 50 years of age → n = 13.
The number of participants in particular age groups 
is shown in Figure 1. In the course of the histopathologi-
cal analysis of the ectocervix and/or endocervix biopsies, 
49.17% of samples were associated with SIL lesions, with 
the following results:
 Ū 23 patients presented CIN 1 — LG SIL, 
 Ū 20 patients showed CIN 2 — HG SIL, 
 Ū 13 patients had CIN 3 — HG SIL, 
 Ū 2 patients presented squamous cell cancer,
 Ū 1 patient showed adenocarcinoma,
 Ū 61 patients had no SIL. 
The incidence of individual histopathological diagnoses 
with reference to particular age groups is shown in Figure 2.
The average age of patients was 28, with 19 years of 
age as the youngest, median: 28, and 66 years of age as 
the oldest.
Results of molecular HR HPV E6/E7  
mRNA test
Test sensitivity in patients with the histopathological 
diagnosis of low-grade squamous intraepithelial lesion was 
estimated at 82.6%. 
Test sensitivity in patients with the histopathological 
diagnosis of high-grade squamous intraepithelial lesion 
was estimated at 86.1% which is shown in Figure 3 with 
reference to particular age groups.
Test sensitivity of patients with the histopathological 
diagnosis of both high- and low-grade squamous intraepi-
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thelial lesion a was estimated at 84.7% with reference to 
particular age groups is presented in Figure 4. 
Test specificity in patients with the histopathological 
diagnosis of both high- and low-grade squamous intraepi-
thelial lesion was estimated at 54.1%, which is shown in 
Figure 5 with reference to particular age groups.
The sensitivity value of the HR HPV E6/E7 mRNA test 
increases with the patients’ age up to 50 years of age, and 
then decreases. 
Sensitivity of detecting squamous intraepithelial lesions 
by means of this test was the highest in the age group of 
40–49 years and above 50 years of age.
Among Pap-test diagnoses listed below: ASC-H, LSIL, 
HSIL and cervical squamous cell carcinoma, a correlation was 
found between the diagnosis of pathology and the presence 
of HR HPV mRNA test. Only in the case of ASC-US diagnosis, 
in most cases the presence of HR HPV E6/E7 mRNA was not 
confirmed. Among the Pap-tests in which no pathology was 
found (NILM), in most cases the presence of HR HPV mRNAs 
was not confirmed. The results are presented in Figure 6. 
The histopathological diagnoses were also taken into 
account — in the case of confirmed pathology, i.e. LGSIL, 
HGSIL and cervical squamous cell carcinoma , the presence 
of HR HPV E6/E7 mRNA was confirmed in the majority of 
cases. On the other hand, tests for the presence of HR HPV 
E6/E7 mRNA are still not proper to detect glandular dysplasia 
(Adenocarcinoma). The results are presented in Figure 7.
There were statistically significant differences in the 
presence of HR HPV E6/E7mRNA and the occurrence of 
pathology found in cervical biopsy (p = 0.00001). The de-
pendencies in all age groups were also tracked. Only in the 
group of the youngest patients no statistically significant 
differences were found (p > 0.05). In contrast, in the other 
age groups, statistically significant differences were found- 
in the group of women aged 30–39 (p = 0.01491) and in 
the group of women over 50 (p = 0.01086). The strongest 
relationship was observed in the group of patients aged 
40–49 (p = 0.00082).
DISCUSSION
According to the paper by Sørbye et al. published in 
2014, diagnostic tests detecting HR HPV E6/E7 mRNA are 
characterized by a higher specificity than tests identify-
ing HR HPV DNA. Comparative studies were conducted in 
Norway in a group of over 300 patients with abnormal Pap 
test, diagnosed with ASC-US or LSIL according to TBS. Posi-
tive predictive value for HSIL histopathological diagnosis in 
terms of HR HPV DNA molecular test was 21.5%, whereas 
for HR HPV E6/E7 mRNA test it was 34.6%. What is more, 
HR HPV DNA test was characterised by a higher sensitivity 
than the HR HPV E6/E7 mRNA test and detected more cases 
of histopathologically confirmed high-grade squamous in-
traepithelial lesion of uterine cervix [16].
Figure 4. mRNA test sensitivity for LGSIL nd HGSIL
Figure 5. mRNA test specifity
Figure 6. The incidence of mRNA positive and negative results 
according to PAP tests
Figure 7. The incidence of mRNA positive and negative results 
according to histopathological diagnoses
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Yao Yl et al. in 2017 confirmed the relevance of HR HPV 
E6/E7 mRNA test in monitoring HR HPV positive patients. In 
the abovementioned paper no statistically relevant differ-
ence was shown between the sensitivity and specificity 
of the Pap test and HR HPV E6/E7 mRNA test in detect-
ing HSIL lesions among HPV positive patients. Moreover, 
the sensitivity and specificity of the abovementioned test 
was estimated at 89.52% and 48.96% respectively in the 
diagnosis of high-grade squamous intraepithelial lesion of 
uterine cervix. Additionally, the percentage of positive HR 
HPV E6/E7 mRNA test results was significantly higher in the 
histopathological HSIL diagnoses than LSIL [17].
According to a 2013 analysis by Perez Castro et al., HR 
HPV DNA tests are characterized by a high sensitivity, but 
a relatively low specificity in identifying uterine cervix onco-
logical pathologies. Due to this fact, new and more precise 
enhanced diagnostic methods are anticipated which could 
be employed in patients with abnormal cytology results, 
namely ASCUS or LSIL. It is vital to notice that test detect-
ing HR HPV E6/E7 mRNA test may significantly increase the 
molecular tests specificity in identifying HSIL lesions, while 
retaining high sensitivity and negative predictive value. 
In the already mentioned paper by Perez Castro et al., the 
HR HPV E6/E7 mRNA test sensitivity for low-grade lesions, 
i.e. LSIL, was estimated at 81.3%, whereas for high-grade 
lesions, that is HSIL, at 84.1%. Additionally, positive predic-
tive value (PPV) was estimated at 97.4% for HSIL lesions. In 
the summary, the authors confirm the relevance of HR HPV 
E6/E7 mRNA test in the diagnosis of HR HPV DNA positive 
population [18].
Fontecha et al. in their paper confirmed the high speci-
ficity of HR HPV E6/E7 mRNA test in HPV positive patient 
population, where progression of squamous intraepithelial 
lesions occurred in a 2-year observation period. In this paper, 
the molecular test was characterised by 100% sensitivity in 
HSIL lesions detection [19].
Combining the aforementioned methods, i.e. PAP test 
and molecular diagnostics detecting HR HPV E6/E7 mRNA, 
may significantly contribute to the earlier and more pre-
cise detection of cervical neoplasia pathology in high-risk 
patients groups [20]. Furthermore, the aforesaid manage-
ment algorithm may also considerably influence the num-
ber of surgical procedures which is particularly crucial in 
pregnant patients. In addition, the future identification of 
patients with the HSIL and cervical cancer risk development 
on the basis of a negative molecular test result will allow 
for a decrease in the numbers of invasive cervical biopsy 
procedures. What is more, the conducted analysis substan-
tiates the diagnostic value of molecular tests enabling the 
detection of uterine cervix precancerous and cancerous 
lesions in pregnant patients. 
Verification diagnostics of abnormal cytology results in 
pregnant patients constitutes a difficult task, lacking par-
ticular algorithms and guidelines. Furthermore, colposcopic 
examination in pregnancy is extremely difficult to interpret, 
and thus involves human error risk due to the examination 
high subjectivity level. A gynaecologist has to frequently 
consider the validity of a comprehensive surgical procedure, 
that is a cervical biopsy, and the risk of complications in 
normally developing pregnancy in patients with question-
able cytology results, according to The Bethesda System. In 
fact, ASCUS and LSIL cytological diagnosis constitutes the 
most frequent abnormal result in pregnant patients [21].
In the 2017 paper, Cobas and Aptima tests were com-
pared. The analysis included over 1800 patients with the 
histopathological HSIL diagnosis. Both tests were character-
ized by high sensitivity. However, the Aptima test possessed 
a statistically higher specificity in detection of high-grade 
lesions, i.e. HSIL, in comparison to the Cobas test which was 
estimated at 41% and 13% respectively. Positive predictive 
value of the Aptima and Cobas tests amounted to 41% and 
13% respectively, whereas test accuracy was equal to 50% 
and 25% respectively. High specificity of the Aptima test, 
combined with its sensitivity, significantly influences cost 
reduction of verification diagnostics in abnormal cytology 
results and positive results of HR HPV DNA tests. It is crucial 
to bear in mind the fact that the Aptima test detects 14 types 
of HR HPV E6/E7 mRNA [22].
In the paper by Duvlis et al., 413 patients were analysed 
with both normal and abnormal cytology results. In all pa-
tients, the DNA and mRNA tests detecting HR HPV virus 
types were conducted. The test identifying E6/E7 mRNA 
transcripts of HPV 16, 18, 31, 33 and 45 was characterized by 
50% specificity and 62% positive predictive value in the HSIL 
detection. In comparison, the specificity of HR HPV DNA test 
was equal to 18%. What is more, the authors emphasise the 
fact that the introduction of modern molecular diagnostics 
may significantly decrease the number of surgical proce-
dures, and thus lower the costs associated with colposcopic 
examinations and cervical biopsies [23].
In 2017 Granados et al. confirmed the relevance of HR 
HPV E6/E7 mRNA test in patients under 35 years of age in 
detection of HSIL lesions. The Aptima test was characterised 
by a slightly higher sensitivity comparing to a liquid-based 
cytology in the diagnosis of CIN 2+ in 5000 patients aged 
25–65. Furthermore, Aptima test presented 100% sensitivity 
in HSIL lesion detection. On the other hand, the sensitivity 
of cytological examination in the group of patients with the 
positive Aptima HPV molecular test result was estimated at 
60.6% [24].
Cadagrande et al. in a 2016 paper confirmed high 
specificity and negative predictive value of HR HPV 
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E6/E7 mRNA test in patients with LSIL lesions, or without 
cervical pathologies. In addition, in patients diagnosed 
with ASCUS and LSIL, HR HPV E6/E7 mRNA positive test 
was more frequent. Moreover, in all subjects with nega-
tive molecular test result, i.e. with no expression of the 
genetic material, the Pap test result was also within the 
normal range — NILM (negative for intraepithelial lesion 
and malignancy) [25].
CONCLUSIONS
High-grade squamous intraepithelial lesion constituted 
the most frequent lesion in women with abnormal cytologi-
cal test results, as well as with the positive results of HR HPV 
E6/E7 mRNA test. 
Furthermore, HR HPV E6/E7 mRNA test identifying neo-
plastic lesions and cervical cancer is characterised by a high 
relevance which is reflected by means of sensitivity and 
specificity. In fact, test sensitivity and specificity increased 
with the age in the group of patients up to 50 years old. 
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